We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

124 hedge funds and large institutions have $378M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 20

95% more capital invested

Capital invested by funds: $194M → $378M (+$184M)

19% more funds holding

Funds holding: 104 → 124 (+20)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 32

81% less call options, than puts

Call options by funds: $596K | Put options by funds: $3.22M

Holders
124
Holders Change
+20
Holders Change %
+19.23%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
40
Increased
32
Reduced
32
Closed
20
Calls
$596K
Puts
$3.22M
Net Calls
-$2.63M
Net Calls Change
-$2.25M

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$35.7M
2
Victory Capital Management
Victory Capital Management
Texas
+$25.7M
3
O
OrbiMed
New York
+$20M
4
CCM
CAAS Capital Management
New York
+$11.5M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.5M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP II
Massachusetts
-$29.6M
2
WP
Woodline Partners
California
-$6.59M
3
SI
Sofinnova Investments
California
-$4.53M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$1.53M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
New York State Common Retirement Fund
51
New York State Common Retirement Fund
New York
$503K – – –
HF
52
HRT Financial
New York
$430K +$460K +41,966 New
LPL Financial
53
LPL Financial
California
$406K -$19.4K -1,775 -4%
First Manhattan
54
First Manhattan
New York
$394K – – –
Principal Financial Group
55
Principal Financial Group
Iowa
$381K +$30.6K +2,795 +8%
QI
56
QS Investors
New York
$374K +$186K +17,000 +88%
Russell Investments Group
57
Russell Investments Group
United Kingdom
$367K -$400K -36,512 -50%
Bank of America
58
Bank of America
North Carolina
$310K +$264K +24,146 +401%
Aberdeen Group
59
Aberdeen Group
United Kingdom
$291K +$92.9K +8,486 +56%
RhumbLine Advisers
60
RhumbLine Advisers
Massachusetts
$286K -$11.5K -1,050 -4%
CSS
61
Cubist Systematic Strategies
Connecticut
$286K +$305K +27,853 New
California State Teachers Retirement System (CalSTRS)
62
California State Teachers Retirement System (CalSTRS)
California
$268K – – –
KAS
63
Kestra Advisory Services
Texas
$261K -$112K -10,249 -29%
Barclays
64
Barclays
United Kingdom
$239K +$195K +17,773 +319%
Susquehanna International Group
65
Susquehanna International Group
Pennsylvania
$227K -$41.7K -3,806 -15%
CAPTRUST Financial Advisors
66
CAPTRUST Financial Advisors
North Carolina
$221K +$110K +10,000 +87%
HP
67
Harbourvest Partners
Massachusetts
$205K +$218K +19,927 New
MSAM
68
Moloney Securities Asset Management
Missouri
$201K +$215K +19,600 New
VOYA Investment Management
69
VOYA Investment Management
Georgia
$200K +$214K +19,522 New
UBS Group
70
UBS Group
Switzerland
$199K +$167K +15,280 +372%
Renaissance Technologies
71
Renaissance Technologies
New York
$198K -$1.22M -111,204 -85%
FIM
72
Freedom Investment Management
Connecticut
$189K +$202K +18,419 New
Qube Research & Technologies (QRT)
73
Qube Research & Technologies (QRT)
United Kingdom
$187K +$200K +18,217 New
Morgan Stanley
74
Morgan Stanley
New York
$174K -$195K -17,773 -51%
B
75
Bailard
California
$170K +$11K +1,000 +6%
1 2
3
4 5

JNCE Hedge Fund Activity: Q1 2021 in Review

124 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2021, worth a combined $378M — up 95% from $194M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new JNCE positions and 20 closed out — a net gain of 20 holders — while 32 added to existing stakes and 32 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $35.7M. The largest seller was TRV GP II, cutting an estimated $29.6M.

  • 124 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2021, up from 104 in Q4 2020.
  • Funds reported $378M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2021, up 95% quarter-over-quarter.
  • 40 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2021 and 20 closed out, a net change of +20 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2021 was PFM Health Sciences, an estimated $35.7M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2021 was TRV GP II, an estimated $29.6M sold.

Based on aggregated 13F filings for Q1 2021.